LUNG Pulmonx Corp. Profit After Tax

Corporate emblem and logo of Pulmonx Corporation (LUNG)

Pulmonx Corporation (LUNG) aims for dominance in the US market through the active implementation of Zephyr systems in clinics. This chart illustrates the company's profit size as calculated by the GURU.Markets system, where the value of -0.04 serves as the baseline indicator. Management is expanding insurance coverage and training specialists, while the scalability of valve supplies for emphysema treatment effectively reduces production costs.

Net Income: Pulmonx (LUNG) for 07/04/2022 - 11/01/2026

Financial and market metric breakdowns for pulmonx.com (LUNG)

- market value and analyst target forecast:
Stock Price Pulmonx|LUNG - Price Target Chart
- market capitalization data:
Market Valuation Pulmonx Corporation|LUNG - Enterprise Value
- issuer book value statistics:
Net Asset Value per Share Pulmonx|LUNG - Company Net Assets|Market Capitalization to Book Value Ratio pulmonx.com|LUNG - Cumulative Company Assets
- debt burden and liquidity indicators:
Aggregate Debt to Capital Pulmonx Corporation|LUNG - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Pulmonx|LUNG - Company Aggregate Debts|Debt to Book Value Pulmonx Corporation|LUNG - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Pulmonx|Quick Liquidity Indicator pulmonx.com
- company profitability and valuation multiples indicators:
LUNG - Net Profit
Fundamental valuation:LUNG, Pulmonx Corp.
Flagship merchandise of Pulmonx Corp.

High metric values signal a risk of overpaying for the asset; therefore, analyzing the company's gross profit helps identify the real sources of daily net income. Rising sales of valves for emphysema treatment stabilize the working capital of Pulmonx Corporation (LUNG), and this chart demonstrates how operational efficiency transforms into the final financial result and market equilibrium.

Key competitors

Dexcom CGM (DXCM) - Net Profit|Company Net Income Penumbra, Inc.|novanta.com - Profit After Tax|Net Profit HAE|INSP - Company Net Income|PROCEPT BioRobotics Inc - Net Income|Net Profit CONMED Inc. CNMD|PLSE: Net Income|inmodemd.com - Profit After Payment of Taxes|PMI: Net Profit|SRDX - Net Financial Result|SENS (Senseonics Holdings) - Net Profit|Net Income NeuroPace Medical (NPCE)|Net Income TCMD (Tactile Systems Technology)|SNWV (sanuwave.com) - Final Profit|Company Net Income Outset Medical OM|ELMD - Net Income|LENSAR, Inc - Net Profit|Company Net Income AVITA Medical Inc|PROF: Net Profit|Company Profit BDMD|EDAP (EDAP TMS SA) - Net Profit|Bovie Medical (APYX) - Net Financial Result|Net Profit ICCM|Net Income telabio.com TELA|Net Profit CTSO (CytoSorbents Corporation)|Net Profit sensushealthcare.com SRTS|ZYXI - Company Net Income|ECOR: Company Net Income|RBOT (vicarioussurgical.com) - Net Income|Inspira Technologies - Final Profit|ICU (SeaStar Medical Holding) - Net Profit|Company Net Income IRIDEX Corp. IRIX|Company Net Income Intelligent Bio Solutions (INBS)|beyondair.net (XAIR) - Annual Net Income|Profusa, Inc. - Net Income|Net Profit STRATA Skin Sciences Inc. SSKN|GlucoTrack - Net Profit|Net Financial Result NanoVibronix Inc. NAOV|Venus Concept (VERO) - Company Net Income|Profit After Tax NUWE (Nuwellis Inc)|Company Net Income Aethlon|Net Income TransEnterix (ASXC)|Net Profit AVGR|BSGM - Company Net Income|Company Net Income Cutera CUTR|KNW: Company Profit|NARI: Net Income|Nevro Medical - Profit After Payment of Taxes|reshapelifesciences.com (RSLS) - Company Net Income|Profit After Tax SILK (silkroadmed.com)